Search

SWG Educational Activities

MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget

Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).

Read more

IVDR resources

IVD Taskforce Videos:Konstanze Döhner

\
 

Monika Brüggemann

IVDR Sessions:

HemaSphere articles:
Critical Implications of IVDR for Innovation in Diagnostics: Input From the BioMed Alliance Diagnostics Task Force
The New EU Regulation on In Vitro Diagnostic Medical Devices: Implications and Preparatory Actions for Diagnostic Laboratories
EU-Wide Access to…

Read more

Board

The EHA Board is the governing body of the association and deals with issues of policy. The Board sets the goals and objectives of the association in conformity with the EHA's statutes. Current members of EHA's Executive Board

Read more

Release of the First Handbook on CAR-T Cells in Europe

Barcelona, 9, February, 2022 – The EBMT and EHA are proud to announce the release of the first-ever open-access book on CAR-T cells to be officially launched during the EBMT-EHA 4th European CAR-T Cell Meeting (Feb 10-12, 2022, Virtual).

Read more

Statement

The European Hematology Association (EHA), a dedicated community of healthcare professionals, who work tirelessly "Towards prevention, cure, and quality of life for all patients with blood disorders", expresses its deep concern and sorrow over the ongoing violence and humanitarian crisis…

Read more

YoungEHA Committee

Current committee members
Mandy Lauw, The Netherlands (Chair)
Anna Kabanova, Italy (Vice Chair)
Elizabeth Macintyre, France (EHA Past President)
Regular members
Anna Avagyan, Armenia 
Nuno Borges, United Kingdom 
Katherine Bridge, United Kingdom 
Lorenzo Brunetti, Italy 
Eleni Gavriilaki, Greece 
William Grey, United Kingdom 
Ruxandra Irimia, Romania
Rafal Machowicz, Poland
Anna Maiques Diaz, Spain
Ana Filipa…

Read more

EU pilot on drug repurposing

Drug repurposing (finding new indications for existing authorized medicines) is increasingly prominent in the debate about improving access to medicines. As stated in EHA’s position paper on access to affordable orphan medicines (Merlini et al.

Read more